CellCarta

Global contract research organization (CRO) providing specialty laboratory services to support the entire drug development cycle.

[CellCarta @CellCarta]

Can't make the talk? Contact our team to learn how we manage biospecimens in clinical programs. https://t.co/k2mpbobcym

[CellCarta @CellCarta]

CellCarta's Simone Spears-Keigan is heading to Boston for the Biospecimen Operations & Biospecimen Management Summit!

[CellCarta @CellCarta]

Don't miss her on the panel with our partners at Slope on Monday at 12:15, discussing how biospecimens are managed throughout their lifecycle with perspectives from sponsors, sites, CROs and lab sites.

[CellCarta @CellCarta]

Barcelona, we'll see you next week ☀️ Our team is attending the European Bioanalysis Forum, and bringing a presentation on Mass Spectrometry in Multiple Myeloma.

Heading to Barcelona? Book a meeting to discuss bioanalysis in clinical programs ➡️ https://t.co/GzceJ4vUOf

[CellCarta @CellCarta]

The CellCarta Team is at ACR Convergence this week! Don't miss the chance to discuss high sensitivity B-cell monitoring and assay design with Maude Boisvert (Abstract Number: 1918), and how we support programs from translation to CDx with Nick Dupuis and Simone Spears.

[CellCarta @CellCarta]

Our scientific experts are at #SITC2026 this week, sharing perspectives and insights on assays, immunotherapy response profiles, and implementing assays across our global infrastructure.

Drop by the posters or Booth #711 to connect with our experts in Phoenix!

[CellCarta @CellCarta]

We have three excellent posters heading to #SITC2026 with the CellCarta team.

We're excited to discuss how our scientists can accelerate your immunotherapy programs goals.

Make sure to drop by the poster sessions on November 7, or visit Booth #711 to learn more!

[CellCarta @CellCarta]

Choosing the right biomarker and clinical strategy can be the difference between a promising therapy reaching patients or stalling before it gets there.

For >25 years, CellCarta has brought scientific rigor to the full spectrum of biomarker development. https://t.co/lADe8QSuYj

[CellCarta @CellCarta]

3️⃣Highly Sensitive B-Cell Monitoring Following B-Cell-Depleting Therapies
➡️ https://t.co/Pbw8658rdB

[CellCarta @CellCarta]

Our flow cytometry and proteomics expertise was on show this week with posters at AAPS PHarmSci360 and the Australasian Cytometry Society.

[CellCarta @CellCarta]

2️⃣ Assessing Inter-instrument Flow Cytometer Alignment ➡️
https://t.co/k4svsRJ60c

[CellCarta @CellCarta]

The CellCarta Team is heading to SITC! This is a great opportunity to grab one-on-one time with the team and discover how our scientific experts develop and deploy assays to collect the critical information your program needs.

Book a meeting here: https://t.co/RkuY4xgiWz

[CellCarta @CellCarta]

Every October, Breast Cancer Awareness Month reminds us why our work is critically important.

To the patients, caregivers, clinicians, and researchers committed to advancing therapeutics in breast cancer: thank you for the work you do.

We are proud to support it.

[CellCarta @CellCarta]

Let's Talk! In our latest webcast, we discuss the realities of building and commercializing CAR-T therapies with Dr. John Rossi, a leader in the field of CAR-T therapy.

Watch the full conversation here: https://t.co/oS28YVhH7K

[CellCarta @CellCarta]

📌 Global Expertise + Local Presence
We're thrilled to be at AusBiotech this week - visit Pierre Gontard and Kevin Lo at Booth 118 in Gold Coast!

Drop by to discuss how we can support your local programs and global trials with our site in Sydney, global labs and expertise.

[CellCarta @CellCarta]

Gold Coast! We're excited to be heading to AusBiotech - come say hi at Booth 118, from October 21 to 23.

Bring your biomarker questions - from multi-modal global trials to keeping your immunology testing local, our experts are excited to discuss how we can support your programs.

[CellCarta @CellCarta]

Announcement! CellCarta and Tivenix are expanding their partnership.

Tivenix's AI-powered platform applies bioinformatics to the epigenetic analysis of cell-free DNA and other tissue-derived signals, supporting precision medicine applications.

Read here: https://t.co/SOPxuW6h21

[CellCarta @CellCarta]

Did we miss you in Basel? We're still available to chat! 👋

We're always excited to discuss the biggest challenges facing your programs, from translational research to CDx commercialization. If we missed you in Basel, send us a message to connect ✉️ https://t.co/0vGUCGWuHy

[CellCarta @CellCarta]

The biomarker discussions continue next week, as we head to Basel for Biomarkers, CDx and Precision Medicine Europe, and NextGen Omics Tech and Data.

Don't miss the chance to discuss you programs with our presenters and panelists, and the team at Booth #10! See you in Basel.